Oncology

#Drug approvals #FDA #Oncology #Rare disease

Positive data for 4SC’s CTCL treatment fuels marketing strategy  

Biotech company 4SC has announced positive new data for its treatment for patients with advanced-stage cutaneous T-cell lymphoma (CTCL).  Findings from the RESMAIN study of 4SC’s resminostat (Kinselby) treatment show that the therapy can postpone disease progression in advanced CTCL. The RESMAIN study is one of… Read More

#News

Research laboratory
#Cancer research #Collaboration #Merck #Oncology #The Institute of Cancer Research

ICR and Merck renew cancer drug discovery alliance

Merck and The Institute of Cancer Research (ICR), London, UK, have renewed their strategic alliance in the discovery and development of new cancer drugs. Scientists in the Centre for Cancer Drug Discovery at the ICR will work with researchers at Merck to discover and develop new… Read More

#Cancer Research #News

Cancer metastasis
#Cancer drug targets #Cancer research #Drug resistance #Oncology #University of Queensland

Novel inhibitors could become new anticancer therapeutics

University of Queensland (UQ) researchers have identified a novel drug target with the potential to overcome drug resistance and prevent tumour regrowth in cancer patients. The newly identified molecule is not currently a target for treatment, opening the potential for drug development. “Drug resistance… Read More

#Cancer Research #News

Stamp of approval
#Chemotherapy #European Commission #Leukaemia #Oncology #Otsuka

European Commission approves oral treatment for leukaemia

The European Commission (EC) has approved INAQOVI (oral decitabine and cedazuridine) as monotherapy for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (AML) who are ineligible for standard induction chemotherapy. INAQOVI, developed by Otsuka Pharmaceutical and Astex Pharmaceuticals, is the first oral hypomethylating… Read More

#News #Regulatory

FDA
#Cancer research #FDA #Immunotherapy #Oncology #Orphan drugs

Orphan status granted to lymphoma maintenance therapy

The US Food and Drug Administration (FDA) has granted Orphan Drug Designation to 4SC’s resminostat (Kinselby) for cutaneous T-cell lymphoma (CTCL). Resminostat is an orally administered class I, IIb and IV histone deacetylase (HDAC) inhibitor that potentially offers an approach to treating different kinds of cancer. Read More

#News #Regulatory

Myeloma cells
#Cancer research #Janns #Janssen #Myeloma #National Institute for Health and Care Excellence (NICE) #Oncology

UK regulator gives green light to combination for multiple myeloma

The National Institute for Health and Care Excellence (NICE) has recommended Darzalex (daratumumab) in combination with lenalidomide and dexamethasone (DLd) for untreated multiple myeloma (MM) for routine use on the NHS in England and Wales. The therapy is now recommended within an NHS setting for the… Read More

#News #Regulatory

CAR-T therapy
#Cancer research #CAR-T #Leucid Bio #MHRA #Oncology #Solid tumours

CAR-T therapy targets over 80% of human tumours

Leucid Bio has been granted clinical trial authorisation by the UK Medicines and Healthcare products Regulatory Agency (MHRA) to initiate a Phase I/II clinical trial evaluating autologous NKG2D-targeted CAR-T cell therapy, LEU011, in patients with relapsed or refractory solid tumours. The open-label, single patient cohort ascending… Read More

#Cancer Research #Editor's Choice #News

T cells
#Cancer research #CAR-T #Immunotherapy #Oncology #T cell activation #Umoja Biopharma

Positive early-stage results for in vivo CAR-T technology

Umoja Biopharma has revealed data from an ongoing non-human primate (NHP) study demonstrating effective, durable, and well tolerated in vivo chimeric antigen receptor (CAR) T cell generation using the company’s VivoVec platform. The data include results from the first four NHPs treated in an ongoing study… Read More

#Cancer Research #News

Bottles of pills
#Cancer research #Drug development #Drug discovery #Oncology #Screening

Identify metabolic target pathways in cancer drug discovery

The regulation of cellular bioenergetics is recognised as a key driver of cancer cell proliferation. Identifying key pathways that modulate bioenergetic metabolism is a promising strategy for developing novel therapeutics for cancer treatment. Discover more in this new App Note from Agilent entitled ‘Rapid Bioenergetic Functional Screening of Anticancer Drug… Read More

#News

#Cancer research #Drug development #Drug discovery #Oncology #Screening

Learn about the rapid bioenergetic functional screening of anticancer drug candidates

The regulation of cellular bioenergetics is recognised as a key driver of cancer cell proliferation. Identifying key pathways that modulate bioenergetic metabolism is a promising strategy for developing novel therapeutics for cancer treatment. In this App Note you will learn: How the Agilent Seahorse XF Real Time ATP rate assay… Read More

#Resources

Lungs
#Antibody #Cancer research #Cancer vaccine #IO Biotech #Lung cancer #Merck #Oncology #Phase II trial

IO Biotech announces data for therapeutic cancer vaccine

IO Biotech, a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on its T-win technology platform, has announced data from a pre-defined interim analysis related to the lung cohort of the Phase II basket trial (IOB-022/KN-D38) with IO102-IO103 in combination with KEYTRUDA (pembrolizumab), Merck’s anti-PD-1 therapy as… Read More

#Cancer Research #News

CAR-T therapy
#Beam Therapeutics #Cancer research #CAR-T #Clinical trial #Leukaemia #Oncology #T cell activation

First base editing therapeutic for T-ALL/T-LL enters trials

The first quadruplex-edited, allogeneic CAR-T cell therapy candidate has entered clinical trials in the US. The first patient has been treated with Beam Therapeutics’ BEAM-201 as part of a Phase I/II clinical study for the treatment of relapsed/refractory T-cell acute lymphoblastic leukaemia/T-cell lymphoblastic lymphoma (T-ALL/T-LL). Read More

#Cancer Research #News

Blood cells
#Artificial intelligence (AI) #Collaboration #Haematology #Intelligent OMICS #Janssen #Multi-omics #Oncology

Intelligent OMICS and Janssen enter AI research collaboration

AI drug discovery company Intelligent OMICS and Janssen Research & Development have agreed a target discovery collaboration to evaluate novel biological targets for the treatment of haematological cancers. The collaboration will combine Intelligent OMICS’ AI platform, which uses multi-omics data and deep learning algorithms to uncover… Read More

#Business & Investment #News

Antibody drug conjugate
#Antibody drug conjugate (ADC) #Cancer research #Genmab #Oncology #Phase III trial #Seagen

Antibody-drug conjugate extends overall survival in cervical cancer

In the Phase III innovaTV 301 trial in recurrent or metastatic cervical cancer patients with disease progression on or after front-line therapy, Tivdak (tisotumab vedotin-tftv), compared with chemotherapy alone, met its primary endpoint of overall survival (OS). An independent data monitoring committee determined that OS crossed… Read More

#Cancer Research #News

Childhood Cancer Awareness Month
#Cancer research #Childhood cancer #Clinical trials #Oncology #Paediatrics

Five key studies into drugs for childhood cancers

DDW’s Diana Spencer highlights five key clinical studies taking a new therapeutic approach to childhood cancers. Over 100 subtypes of childhood cancer exist today and it represents the most common cause of disease-related death in children. However, despite the fact that children’s response to adult cancer… Read More

#Cancer Research #Exclusive Content

#Artificial intelligence (AI) #Breast cancer #Head and neck cancer #Immunotherapy #Long Covid #Monoclonal antibodies #Oncology #Parkinson's #Stem cells

New DDW Highlights podcast out now

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  This week’s headline news features a stem-cell derived Parkinson’s therapy, a monoclonal antibody for… Read More

#News